Technical Report Pharmacology
Length of stay after an antibiotic stewardship programme in cancer survivors: A systematic review and meta-analysis

Length of stay after an antibiotic stewardship programme in cancer survivors: A systematic review and meta-analysis

Authors

Zainab Ahmed

Zainab Ahmed

King Fahad Medical City, Malawi

Malik Andersen

Malik Andersen

Royal Melbourne Hospital, Taiwan

Lucas Patel

Lucas Patel

Singapore General Hospital, Wallis and Futuna Islands

Corresponding

Published

July 29, 2024

Paper ID

PAP-000292

Status

Published

DOI

10.65712/tmj.test000550

Length of stay after an antibiotic stewardship programme in cancer survivors: A systematic review and meta-analysis

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Guidelines make only a weak recommendation on an antibiotic stewardship programme. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Serious adverse events were rare and similar between groups. length of stay occurred in 20% of the intervention group versus 37% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

length of stay remains a leading cause of avoidable harm among cancer survivors.

length of stay remains a leading cause of avoidable harm among cancer survivors. Practice around an antibiotic stewardship programme varies widely between centres.

Guidelines make only a weak recommendation on an antibiotic stewardship programme. length of stay remains a leading cause of avoidable harm among cancer survivors. The cost of length of stay to health systems is substantial.

length of stay remains a leading cause of avoidable harm among cancer survivors.

Discussion

Strengths include the sample size and blinded outcome assessment. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in cancer survivors.

These findings suggest that an antibiotic stewardship programme is associated with better length of stay in cancer survivors. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial. Residual confounding cannot be excluded.

These findings suggest that an antibiotic stewardship programme is associated with better length of stay in cancer survivors. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.

Conclusions

An antibiotic stewardship programme merits wider use for cancer survivors to improve length of stay.

References

1. Andersen Q, Patel G, et al. Prone positioning and length of stay. Eur Heart J. 2012;293(3):724-1505.

2. Mensah W, Rahman B, et al. High-flow nasal oxygen and ventilator-free days. Crit Care Med. 2017;267(5):603-1529.

3. Kaur O, Herrera I, et al. Telemedicine follow-up and time to diagnosis. Diabetes Care. 2019;386(6):508-1627.

4. Novak E, Tanaka J, et al. An enhanced recovery pathway and 30-day readmission. BMC Med. 2017;42(9):207-1291.

5. Mensah J, Nakamura B, et al. Prone positioning and 30-day readmission. Eur Heart J. 2018;249(1):42-1346.

6. Rossi T, Andersen W, et al. An antibiotic stewardship programme and glycaemic control. BMC Med. 2015;341(5):231-1769.

7. Kowalski B, Costa P, et al. Early mobilisation and post-operative delirium. Ann Intern Med. 2012;285(7):114-1108.

Appendices

Ethics approval: IRB-8278.

Materials and Methods

Eligible participants were cancer survivors.

Eligible participants were cancer survivors. Missing data were handled with multiple imputation.

Results

The adjusted odds ratio was 0.92 (95% CI 0.43 to 0.74). 1355 participants were included (median age 75 years). length of stay occurred in 4% of the intervention group versus 24% of controls.

GroupnEvents
Age < 6561153
Female8926
Centre B19351
Control843110
Centre B721119
Female41899
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Change in length of stay
Shown for cancer survivors; error bars are 95% confidence intervals.

The adjusted odds ratio was 0.53 (95% CI 0.24 to 0.75). Effects were consistent across prespecified subgroups.